# To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years

> **NCT05389137** · PHASE4 · UNKNOWN · sponsor: **Wuhan Institute of Biological Products Co., Ltd** · enrollment: 360 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Inavtivated Quadrivalent Influenza Virus Split Vaccine

## Key facts

- **NCT ID:** NCT05389137
- **Lead sponsor:** Wuhan Institute of Biological Products Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-02
- **Primary completion:** 2022-05
- **Final completion:** 2022-10
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389137, "To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 Years". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05389137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*